Cardiol Therapeutics (TSX:CRDL) - Hisse Senedi Fiyatı, Haberler ve Analizler

CRDL Stoklara Genel Bakış

CRDL temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( CA$0 )

Hissedarlar geçen yıl sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Cardiol Therapeutics Inc. Rakipler

Small Pharma

TSXV:DMT

CA$50.4m

Planet 13 Holdings

CNSX:PLTH

CA$195.1m

Organigram Holdings

TSX:OGI

CA$220.4m

NervGen Pharma

TSXV:NGEN

CA$160.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Cardiol Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$2.18
52 Haftanın En Yüksek Seviyesi	CA$4.26
52 Haftanın En Düşük Seviyesi	CA$1.07
Beta	0.70
11 Aylık Değişim	-17.42%
3 Aylık Değişim	-21.01%
1 Yıllık Değişim	89.57%
33 Yıllık Değişim	-21.86%
5 Yıllık Değişim	-43.52%
Halka arzdan bu yana değişim	-47.47%

Son Haberler & Güncellemeler

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12

Recent updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Jan 06

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Sep 13

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

May 24

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Dec 09

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Aug 19

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Apr 18

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Jan 03

Hissedar Getirileri

	CRDL	CA Pharmaceuticals	CA Pazar
7D	-18.0%	-6.1%	0.7%
1Y	89.6%	-22.3%	21.7%

Getiri vs. Endüstri: CRDL geçen yıl % -22.3 oranında getiri sağlayan Canadian Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: CRDL geçen yıl % 21.7 oranında getiri sağlayan Canadian Piyasasını aştı.

Fiyat Oynaklığı

Is CRDL's price volatile compared to industry and market?
CRDL volatility
CRDL Average Weekly Movement	8.6%
Pharmaceuticals Industry Average Movement	11.5%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.6%
10% least volatile stocks in CA Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: CRDL son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: CRDL 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2017	n/a	David Elsley	www.cardiolrx.com

Klinik aşamalı bir yaşam bilimleri şirketi olan Cardiol Therapeutics Inc. kalp hastalıklarının tedavisi için anti-fibrotik ve anti-enflamatuar tedavilerin araştırılması ve geliştirilmesine odaklanmaktadır. Şirketin öncü ürün adayı CardiolRx, akut miyokarditte ve tekrarlayan perikardit tedavisinde CardiolRx'in etkinliğini ve güvenliğini değerlendirmek için Faz II çok uluslu, randomize, çift kör ve plasebo kontrollü bir çalışma yürütmektedir. Şirket ayrıca kalp yetmezliği tedavisi için klinik öncesi geliştirme aşamasında olan subkutan uygulama için CRD-38 enjeksiyonunu geliştirmektedir.

Cardiol Therapeutics Inc. Temel Bilgiler Özeti

Cardiol Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CRDL temel i̇stati̇sti̇kler
Piyasa değeri	CA$182.97m
Kazançlar(TTM)	-CA$36.14m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-4.8x

F/K Oranı

CRDL aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CRDL gelir tablosu (TTM)
Gelir	CA$0
Gelir Maliyeti	CA$0
Brüt Kâr	CA$0
Diğer Giderler	CA$36.14m
Kazançlar	-CA$36.14m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.45
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

CRDL uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CRDL Stoklara Genel Bakış

Risk Analizi

Cardiol Therapeutics Inc. Rakipler

TSXV:DMT

CA$50.4m

CNSX:PLTH

CA$195.1m

TSX:OGI

CA$220.4m

TSXV:NGEN

CA$160.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Revenue and earnings growth

Cardiol Therapeutics Inc. to Advance CardiolRx into A Late-Stage Trial in Patients with Recurrent Pericarditis

Cardiol Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $13.5 million.

Cardiol Therapeutics Inc. has filed a Follow-on Equity Offering.

Cardiol Therapeutics Inc. Achieves Target Patient Enrollment in its Phase II Archer Trial Investigating CardiolRxTM for Acute Myocarditis

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Recent updates

New major risk - Revenue and earnings growth

Cardiol Therapeutics Inc. to Advance CardiolRx into A Late-Stage Trial in Patients with Recurrent Pericarditis

Cardiol Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $13.5 million.

Cardiol Therapeutics Inc. has filed a Follow-on Equity Offering.

Cardiol Therapeutics Inc. Achieves Target Patient Enrollment in its Phase II Archer Trial Investigating CardiolRxTM for Acute Myocarditis

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Cardiol Therapeutics Announces Completion of the Maveric Phase II Study in Recurrent Pericarditis with Results to Be Presented At the American Heart Association Scientific Sessions 2024

President recently bought CA$138k worth of stock

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Cardiol Therapeutics Inc., Annual General Meeting, Jul 26, 2024

New major risk - Share price stability

New minor risk - Share price stability

Cardiol Therapeutics Inc. Announces It Has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Cardiol Therapeutics Inc. Announces Massachusetts General Hospital as the 8th Major Medical Centre Participating in MAvERIC-Pilot

New minor risk - Shareholder dilution

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Inc. Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in Model of Heart Failure with Preserved Ejection Fraction

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in Archer, A Phase II Trial of Cardiolrx™ for the Treatment of Acute Myocarditis

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to CA$0.37 loss

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2023

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Phase II Study Evaluating Cardiolrx for the Treatment of Recurrent Pericarditis

Cardiol Therapeutics Inc. Announces the Initiation of a Phase II Open-Label Pilot Study (NCT05494788), to Investigate the Tolerance, Safety, and Efficacy of CardiolRx in Patients with Recurrent Pericarditis

No longer forecast to breakeven

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

High number of new and inexperienced directors

Price target increased to CA$4.50

Cardiol Therapeutics Inc. Announces Study Results Demonstrating Protective Effects of Cardiolrx in A Model of Acute Pericarditis

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating Cardiolrx Inhibits

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Consensus forecasts updated

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Archer, A Phase II Clinical Trial of Cardiolrx(TM) for Treatment of Acute Myocarditis

Consensus forecasts updated

Consensus forecasts updated

Cardiol Therapeutics Inc. Announces Board Appointments

Cardiol Therapeutics Announces FDA Investigational New Drug Application Authorization for Multicenter Phase II Open-Label Pilot Study of Cardiolrx for Recurrent Pericarditis

Price target decreased to CA$7.50

High number of new and inexperienced directors

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2022

We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Independent Chairman recently bought CA$121k worth of stock

Price target decreased to CA$10.83

Cardiol Therapeutics Inc. Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments in Lancer Trial

High number of new and inexperienced directors

No longer forecast to breakeven

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Independent Director exercised options to buy CA$97k worth of stock.

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (Ind) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Cardiol Therapeutics Common Shares Class A Deleted from Other OTC

High number of new directors

Price target increased to CA$9.57

Cardiol Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 22.0032 million.

Cardiol Therapeutics Announces First Patient Enrolled in Lancer, A Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Consensus forecasts updated